BNP Paribas Knock-Out NOVN/ DE000PC3FLC4 /
10/01/2025 16:47:06 | Chg.+0.080 | Bid17:19:45 | Demandez à17:19:45 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
2.920EUR | +2.82% | - Bid taille: - |
- Ask la taille: - |
NOVARTIS N | 118.3886 CHF | 31/12/2078 | Put |
GlobeNewswire
30/07/2024
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/07/2024
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire
26/06/2024
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
13/06/2024
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
13/05/2024
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire
16/04/2024
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
11/04/2024
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire
14/03/2024
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
28/02/2024
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
28/02/2024
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
10/01/2024
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
05/01/2024
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page